多模式头颈癌治疗中卒中的全球发病率、死亡率和危险因素——系统综述与Meta分析
该系统综述与Meta分析检索截至2024年7月的文献,纳入69项研究共258850例头颈癌患者,评估治疗后卒中发病率、死亡率及预测因素。头颈癌患者卒中全球累积发病率为4.1%,高于一般人群(HR 1.69);卒中死亡率从2010年前的28.5%降至2010-2024年的14.5%,放化疗后死亡率最高(39.3%)。
要点
- 头颈癌患者卒中全球累积发病率为4.1%,高于一般人群(HR 1.69,95%CI 1.24-2.31,p=0.001)。
- 放化疗后卒中死亡率为39.3%,高于放疗后的21%。
- 卒中死亡率从2010年前的28.5%降至2010-2024年的14.5%。
核心结论
- 这是首个分析卒中与头颈癌治疗关联的系统综述。
- 卒中死亡率从2010年前的28.5%降至2010-2024年的14.5%,放化疗组死亡率最高(39.3%)。
- 鉴于卒中在放化疗后36-45个月发生,3-4年内进行筛查方案至关重要。
研究设计与样本
- 系统综述与Meta分析,检索Pubmed、Web of Science、Embase和ScienceDirect从建库至2024年7月的文献。
- 纳入69项研究,共258850例头颈癌患者。
- 采用随机效应Meta分析评估累积发病率和死亡率,并使用风险比(HR)评估与头颈癌治疗相关的危险因素。
- 对发病率和死亡率进行了2010年前后时期的亚组分析。
主要发现
- 头颈癌卒中全球累积发病率为4.1%(95%CI 3.3%-5.0%),2010年前后相似(4.4% vs 4.0%)。
- 接受放化疗的患者卒中发病率为4.9%(95%CI 3.5%-6.7%),首次卒中中位时间为45个月(范围14-51.7个月)。
- 接受放疗后卒中发病率为3.8%(95%CI 2.7%-5.3%),卒中中位时间为36个月(范围6.8-130个月)。
- 头颈癌患者卒中发病率高于一般人群(HR 1.69,95%CI 1.24-2.31,p=0.001)。
- 卒中死亡率从2010年前的28.5%(95%CI 11.6%-54.9%)降至2010-2024年的14.5%(95%CI 11.6%-17.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck cancer (HNC) due to its nature and proximity to essential vasculature, along with different treatments, can lead to stroke, significantly contributing to morbidity and mortality. Our aim is to systematically evaluate the association of stroke incidence, mortality, and predictors with HNC treatment. METHODS: Pubmed, Web of Science, Embase, and ScienceDirect were searched from inception to July 2024 for articles reporting stroke incidences, mortality, or associated risk factors following treatment in HNC patients. A random-effects meta-analysis assessed cumulative incidence and mortality rates with proportional analysis and risk factors using hazard ratios (HRs) associated with HNC treatment. Subgroup analyses of incidence and mortality were conducted for pre- and post-2010 periods, reflecting changes in stroke protocols. RESULTS: Out of 1561 studies, 69 studies with 258 850 HNC patients were included. The global cumulative incidence of stroke in HNC was 4.1% (95% CI: 3.3%-5.0%), with similar rates before and after 2010 (4.4% vs. 4.0%). In patients undergoing chemoradiotherapy (CRT), stroke incidence was 4.9% (95% CI: 3.5%-6.7%) with a median time to first stroke of 45 months (range: 14-51.7 months). Following radiation therapy (RT), stroke incidence was 3.8% (95% CI: 2.7%-5.3%) with a median time to stroke of 36 months (range: 6.8-130 months). The incidence rates of stroke in HNC patients were higher compared to the general population (HR: 1.69, 95% CI: 1.24-2.31, p = 0.001). Stroke mortality decreased from 28.5% (95% CI: 11.6%-54.9%) pre-2010 to 14.5% (95% CI: 11.6%-17.9%) 2010-2024. Stroke mortality was 39.3% (95% CI: 17.8%-66.0%) post-CRT and 21% (95% CI: 7.2%-47.7%) post-RT. Hypertension (HR = 1.75), diabetes (HR = 1.71), and age > 65 (HR = 2.17) increased stroke risk (p < 0.0001 for all). Geographically, South Korea (6.6%) had the highest incidence of stroke. CONCLUSION: This is the first systematic review to analyze the association between stroke and HNC treatment. Stroke mortality decreased from 28.5% to 14.5% (pre-2010 vs. 2010-2024), with the highest mortality in the CRT group (39.3%). Given that stroke occurs 36-45 months after CRT, a screening protocol within 3-4 years is crucial.
引用
- Vasudevan SS, Ericksen E, Albornoz V, et al. Global Incidence, Mortality, and Risk Factors of Stroke in Multi-Modality Head and Neck Cancer Treatment-A Systematic Review and Meta-Analysis. Head Neck. 2025. PMID: 39943713. doi:10.1002/hed.28109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。